-

Brenus Pharma unveils promising pre-clinical results extrapolating human conditions in major international congresses.

LYON, France--(BUSINESS WIRE)--Brenus Pharma announces that pre-clinical advancements of its inaugural research program were presented at the 7th CICON (International Cancer Immunotherapy) Conference in Milan, Italy (September 20-23) and will be showcased at the 38th Annual SITC (Society for Immunotherapy of Cancer) Congress in San Diego, CA, USA (November 1-5)

These communications focus on pre-clinical validation of new developments of the first product generated by the STC Platform, STC-1010, which targets colorectal cancer in a first line of treatment.

CONFERENCE

TITLE

AUTHORS

RESULTS

CICON23

P119: Allogenic Tumor Cell-Based Vaccine to Treat Colorectal Cancer: Development and Preclinical Validation

SEE POSTER

SITC23

Stimulated Tumor Cells (STC) Vaccine Induce Response in Colorectal Cancer

TO COME

Benoit PINTEUR, (Pharm.D), Co-Founder and Chief Scientific Officer at Brenus Pharma explains: "After testing the STC product on colorectal cancer models in syngeneic immunocompetent mice (in vivo), where results have shown improved overall survival and enhanced immune response with STC-1010, we tested new models (ex vivo, in ovo) to enhance human extrapolation to validate the STC-1010 biological mechanism of action and replicate excellent results on human colorectal cancer models. All our efforts are now focused on regulatory approvals and batch production for the clinical trial in 2024."

About STC Platform: "Stimulated-Tumor-Cells" is the first technology platform that generates cancer vaccines, based on cells that are stimulated to reproduce antigenic relapsing-tumor signatures; and haptenized to educate the immune system against resistant tumors. It breaks through current limitations by efficiently treating solid tumors, ensuring cost and supply control.

For further information: www.brenus-pharma.com

Contacts

CONTACT BRENUS
Marion Brun
Communication Manager
contact@brenus-pharma.com
+ 33 (0)7 87 76 87 72

Industry:

Brenus Pharma

Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)
Hashtags
#Biotech
#CICON23
#Cancervaccine
#Clinical
#Colorectalcancer
#Healthcare
#Immunotherapy
#SITC23

Contacts

CONTACT BRENUS
Marion Brun
Communication Manager
contact@brenus-pharma.com
+ 33 (0)7 87 76 87 72

Social Media Profiles
Follow Brenus Pharma
More News From Brenus Pharma

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients

LYON, France--(BUSINESS WIRE)--Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during do...

Brenus Pharma Expands Its Global Scientific Advisory Board With Us Immuno-Oncology Expert Prof. Olivera J. Finn

LYON, France & PITTSBURGH--(BUSINESS WIRE)--Brenus Pharma, a clinical-stage biotechnology company developing first-in-class in vivo immunotherapies for solid tumors, announced the appointment of Olivera J. Finn, Distinguished Professor at the University of Pittsburgh School of Medicine, to its Scientific Advisory Board (SAB). This strategic addition strengthens Brenus’ international SAB as the company advances its proprietary Stimulated Ghost Cell (SGC) platform and lead candidate STC-1010 towa...

Brenus Pharma Announces First Patients Dosed in its First-in-Human Trial Evaluating STC-1010, a Next-Generation Immunotherapy

LYON, France--(BUSINESS WIRE)--Brenus Pharma today announced that first patients have been successfully dosed in its first-in-human clinical trial evaluating STC-1010, the company’s lead in vivo immunotherapy candidate developed through its proprietary off-the-shelf platform. Three patients have already been enrolled in the study. The first completed eight weeks of treatment with no adverse events attributed to the investigational therapy. This trial targets patients with unresectable, locally...
Back to Newsroom